Physician profile
John Mark Tohlen
NPI 1598298077
$1,209.64
in general payments reported to CMS, 2019-2025
28 companies · $46.66 in 2025
The $46.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $305 · 2021: $753 · 2023: $63.73 · 2024: $41.75 · 2025: $46.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $141.88 | 2020-2021 | |
| Astellas Pharma US INC | $121.52 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $64.39 | 2021 | |
| Amarin Pharma, INC. | $63.90 | 2020-2021 | |
| Novo Nordisk INC | $54.58 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $51.39 | 2021-2025 | M-M-R II, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $50.19 | 2021 | |
| Pfizer INC. | $49.92 | 2023-2024 | |
| Amgen INC. | $48.64 | 2020-2021 | |
| Lilly USA, LLC | $41.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.60 | 2021 | |
| Genentech USA, INC. | $32.79 | 2020-2021 | |
| Glaxosmithkline, LLC. | $30.23 | 2021 | |
| Exact Sciences Corporation | $29.23 | 2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.13 | 2021 | |
| Daiichi Sankyo INC. | $19.97 | 2020 | |
| Abbott Laboratories | $18.42 | 2024 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.98 | 2021 | |
| Ibsa Pharma INC. | $16.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.81 | 2021 | |
| Cranial Technologies, INC | $15.30 | 2023 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $15.05 | 2021 | |
| Allergan, INC. | $14.91 | 2020 | |
| Currax Pharmaceuticals LLC | $13.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.13 | 2021 | |
| Alnylam Pharmaceuticals INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mark Tohlen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.